Last updated on August 2018

Clinical Study of AK1820 (Isavuconazonium Sulfate) for the Treatment of Deep Mycosis


Brief description of study

The objective of this study is to investigate the safety and efficacy of administering 372.6 mg of AK1820 (isavuconazonium sulfate) intravenously or orally to adult Japanese patients with deep mycosis. The primary endpoint is safety (percentage of patients with adverse events after starting the study treatment).

Clinical Study Identifier: NCT03471988

Contact Investigators or Research Sites near you

Start Over

Asahi Kasei Pharma Corporation

Research site
Nagoya, Japan
  Connect »

Asahi Kasei Pharma Corporation

Research site
Yokohama, Japan
  Connect »

Asahi Kasei Pharma Corporation

Research site
Abeno-Ku, Japan
  Connect »

Asahi Kasei Pharma Corporation

Research site
Kiyose, Japan
  Connect »

Asahi Kasei Pharma Corporation

Research site
Shinagawa-Ku, Japan
  Connect »

Asahi Kasei Pharma Corporation

Research site
Nagasaki, Japan
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.